An editorial notes that for such a rare cancer, when collaboration in large clinical trials is hindered by the few cases and vast geographical distance between them, systematic reviews and thorough meta-analyses are necessary to advance the standard of care. However, clinical trials remain the gold standard, and the retinoblastoma clinical and scientific community should rise to this challenge, following the example adopted in their settings of the rest of the paediatric oncology field.